Brett Conrad Joins Luventix as Advisor
Luventix, a leading innovator in Intelligent Disease Diagnostics, is pleased to announce that Brett Conrad has joined the organization as an Advisor.
Brett brings an extensive background in investment management, retail, technology, and consumer products, with a wealth of experience across multiple industries. As the Managing Member of Longboard Capital Advisors, LLC, he has demonstrated expertise in investment management and analysis, focusing on clean technology, including solar, wind, pollution abatement, waste-to-energy, smart grid, and efficiency systems.
Brett's distinguished career includes serving as President of Lululemon Athletica USA, where he successfully launched the Canadian yoga apparel manufacturer and retailer in the U.S. market with funding from Highland Capital and Advent International. He has also held leadership positions as Founder and CEO of GLIDE Web Systems, COO of Conversant Solutions, and SVP of Marketing at Ride Snowboards before its acquisition by K2 Sports. . His specialties encompass finance, investment management, communication and collaboration systems, retail and wholesale consumer products, and franchising systems. His deep understanding of lifestyle sports industries, including snowboarding, cycling, surfing, skateboarding, rock climbing, and yoga, makes him a valuable asset to the Luventix team.
"We are thrilled to welcome Brett Conrad to our advisory team," said George Holmes, CEO of Luventix. "His strategic insights and leadership across diverse industries will play a crucial role in supporting our growth and innovation in the diagnostics field."
About Luventix
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment, and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com.
Media Contact:
